You are here: Handbooks » Unit handbook » Anticoagulation

 

Initiation of full anticoagulation with heparin

In patients with renal failure the use of unfractionated heparin is still recommended for full anticoagulation . The use of LMW heparins in fully anticoagulating doses is not recommended as their action is prolonged and may be potentiated by uraemic bleeding tendency.

Adjust heparin infusion rate as follows:
APTT ratio
Heparin infusion (1000 units/ml)
Recheck APTT
> 5.0 Stop for 1h, then decrease by 500 units/h 2-6h
4.1 - 5.0 Decrease by 300 units/h (0.3ml Pumphep/h) 2-6h
3.1 - 4.0 Decrease by 100 units/h (0.1ml Pumphep/h) 2-6h
2.6 - 3.0 Decrease by 50 units/h (0.05ml Pumphep/h) 2-12h
1.5 - 2.5 No change within 24h*
1.2 - 1.4 Increase by 200 units/h (0.2ml Pumphep/h) 2-12h
< 1.2 Increase by 400 units/h (0.4ml Pumphep/h) 2-6h

* Sooner if APTT has been unstable

Special circumstances
  • Urgent reversal of anticoagulation: contact haematologist.
  • Lupus anticoagulant may render APTT results meaningless, and require more complex assays.
  • For further information on these or other issues please contact the consultant haematologist.


 

Warfarinisation

Schedule for induction of warfarin therapy
From Fennerty et al, Br Med J (1988) 297:1285-5
Day
INR
(best taken 0900-1000)
Dose in mg
(best given 1700-1800)
1
<1.4
This schedule is not applicable if INR is 1.4 or higher - give smaller loading dose
10
2
<1.8
1.8
>1.8
10
1
0.5
3
<2.0
2.0-2.1
2.2-2.3
2.4-2.5
2.6-2.7
2.8-2.9
3.0-3.1
3.2-3.3
3.4
3.5
3.6-4.0
>4.0
10
5
4.5
4
3.5
3
2.5
2
1.5
1
0.5
zero
Day
INR
Predicted maintenance dose (mg)
4
<1.4
1.4
1.5
1.6-1.7
1.8
1.9
2.0-2.1
2.2-2.3
2.4-2.6
2.7-3.0
3.1-3.5
3.6-4.0
4.1-4.5
>8
8
7.5
7
6.5
6
5.5
5
4.5
4
3.5
3
miss out next day's dose then give 2mg
4
>4.5
miss two doses then give 1mg


Alternatives to heparin

These may be used in patients with heparin-induced thrombocytopaenia (HIT) or sometimes in those at high risk of haemorrhage.

Epoprostenol (prostacyclin, Flolan®) is a potent vasodilator that inhibits platelet aggregation. A half-life of about 3 mins means that it must be given by continuous infusion but that its efffects wear off quickly. Hypotension, flushing, headache, nausea and vomiting, and other symptoms may occur.

The freeze-dried drug is diluted first with the accompanying diluent and then with saline to 2000 nanograms/ml. Infusion rate is 1-5ng/kg/min, gradually building up the dose over 30 mins before connecting to the machine. At tolerated doses it is usually found to be less effective than heparin at preventing clotting in extracorporeal circuits.

Danaparoid (Orgaran®) is a heparinoid. In the UK available on a named-patient basis. Acts by blocking factor Xa. Has a prolonged action that is greater in renal failure because it is normally renally excreted; monitor Xa levels. Difficult to reverse. Side effects are similar to heparin. In HIT, cross-reactivity may occur in 10%. The following has been used during haemofiltration (an unlicensed indication):

Lepirudin is a recombinant hirudin (anti-thrombin). Activity can be monitored by APTT (aim for ratio 2.0-3.0 versus control) but this does not correlate precisely with plasma hirudin levels. Prolonged excretion in renal failure means that full anticoagulation is practically continuous for patients on alternate day dialysis, and there is no easy way of reversing the anticoagulation. Side effects related to anticoagulation but also fever, allergy, and injection site reactions. Use in haemodialysis is not surprisingly unlicensed but the following protocol has been used:

A hepatically metabolised hirudin with shorter half-life is in development.

 

Heparin-induced thromboctopaenia (HIT-II)

This is caused by platelet factor 4 antibodies, which can activate platelets.  Existing tests often give positive results in patients who do not have the syndrome of:

In patients at highest risk, the acutely ill, there are usually alternative possible explanations for thrombocytopaenia.  Because current alternatives to heparin may be hazardous in themselves, it is important to consider the balance of probabilities and risks.

Reference:  The Heparins:  all a nephrologist should know.  NDT 20:2036-42 (2005) (Hetzel & Suker)

 

Acknowledgements:   Lorna Thomson, Mariana Dimova and Neil Turner were the main authors for this page. It was first published in November 2001, revised November 2006, last amended Wednesday, May 20, 2009.
 

 Up to top

 

Anaemia in renal disease << >> Antimicrobial policies